Monumental Financial Group Inc. Has $1.32 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Monumental Financial Group Inc. increased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,493 shares of the medical research company’s stock after buying an additional 89 shares during the quarter. Agilent Technologies comprises about 0.8% of Monumental Financial Group Inc.’s portfolio, making the stock its 21st biggest position. Monumental Financial Group Inc.’s holdings in Agilent Technologies were worth $1,320,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in A. MV Capital Management Inc. increased its holdings in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. OFI Invest Asset Management bought a new stake in Agilent Technologies during the 3rd quarter worth approximately $25,000. Baystate Wealth Management LLC increased its holdings in Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after purchasing an additional 133 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in Agilent Technologies during the 4th quarter worth approximately $39,000. Finally, Rosenberg Matthew Hamilton increased its holdings in Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares in the last quarter.

Insider Buying and Selling

In related news, Director Heidi Fields sold 1,658 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the transaction, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Rodney Gonsalves sold 4,828 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the transaction, the vice president now owns 21,329 shares of the company’s stock, valued at $3,178,021. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Heidi Fields sold 1,658 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,610 shares of company stock worth $9,220,333.

Analyst Ratings Changes

A number of brokerages have commented on A. Barclays boosted their price objective on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Evercore ISI upped their target price on Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Oppenheimer upped their target price on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and upped their target price for the company from $145.00 to $163.00 in a report on Friday, April 5th. Finally, Citigroup upped their target price on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $141.29.

Agilent Technologies Stock Performance

Shares of NYSE:A traded up $1.37 during trading on Friday, hitting $137.74. 754,945 shares of the company were exchanged, compared to its average volume of 1,245,651. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $151.58. The company has a market cap of $40.36 billion, a PE ratio of 32.80, a P/E/G ratio of 4.17 and a beta of 1.11. The stock has a 50 day moving average of $141.59 and a 200 day moving average of $130.80.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the business posted $1.37 earnings per share. The firm’s revenue was down 5.5% compared to the same quarter last year. As a group, equities research analysts predict that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were given a $0.236 dividend. The ex-dividend date was Monday, April 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.38%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.